Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: A systematic review

International Journal of Antimicrobial Agents

Volumn 39, Issue 1, 2012, Pages 1-10

  Sinnollareddy, Mahipal ^a,b   Peake, Sandra L ^a   Roberts, Michael S ^a,b   Lipman, Jeffrey ^c,d   Roberts, Jason A ^b,c,d  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Antifungal agents; Critically ill; Pharmacodynamics; Pharmacokinetics; Renal replacement therapy

Indexed keywords

ALFENTANIL; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CASPOFUNGIN; CREATININE; FENTANYL; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; LEVOFLOXACIN; MICAFUNGIN; MIDAZOLAM; VORICONAZOLE;

ABSENCE OF SIDE EFFECTS; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CANDIDA; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS HEMOFILTRATION; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DISTRIBUTION VOLUME; DOSE CALCULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; HUMAN; HYDROPHILICITY; INTENSIVE CARE; INVASIVE CANDIDIASIS; LIVER TOXICITY; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NONHUMAN; OPTIMAL DRUG DOSE; PHARMACODYNAMICS; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; SEPSIS; SYSTEMATIC REVIEW; SYSTEMIC MYCOSIS;

EID: 82955177019     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2011.07.013     Document Type: Short Survey

References (80)

1. J.L. Vincent, J. Rello, J. Marshall, E. Silva, A. Anzueto, and C.D. Martin International study of the prevalence and outcomes of infection in intensive care units JAMA 302 2009 2323 2329
2. R. Luzzati, B. Allegranzi, L. Antozzi, L. Masala, E. Pegoraro, and A. Azzini Secular trends in nosocomial candidaemia in non-neutropenic patients in an Italian tertiary hospital Clin Microbiol Infect 11 2005 908 913 (Pubitemid 41535929)
3. O. Marchetti, J. Bille, U. Fluckiger, P. Eggimann, C. Ruef, and J. Garbino Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000 Clin Infect Dis 38 2004 311 320 (Pubitemid 38200105)
4. E.G. Playford, J. Lipman, and T.C. Sorrell Management of invasive candidiasis in the intensive care unit Drugs 70 2010 823 839
5. H. Wisplinghoff, T. Bischoff, S.M. Tallent, H. Seifert, R.P. Wenzel, and M.B. Edmond Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study Clin Infect Dis 39 2004 309 317 (Pubitemid 39050477)
6. M.A. Pfaller, and D.J. Diekema Epidemiology of invasive candidiasis: a persistent public health problem Clin Microbiol Rev 20 2007 133 163 (Pubitemid 46167771)
7. J.L. Vincent, D.J. Bihari, P.M. Suter, H.A. Bruining, J. White, and M.H. Nicolas-Chanoin The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee JAMA 274 1995 639 644
8. C. Alberti, C. Brun-Buisson, H. Burchardi, C. Martin, S. Goodman, and A. Artigas Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study Intensive Care Med 28 2002 108 121 (Pubitemid 34293822)
9. P. Eggimann, J. Garbino, and D. Pittet Epidemiology of Candida species infections in critically ill non-immunosuppressed patients Lancet Infect Dis 3 2003 685 702 (Pubitemid 37345347)
10. A. Lepak, and D. Andes Fungal sepsis: optimizing antifungal therapy in the critical care setting Crit Care Clin 27 2011 123 147
11. J.A. Smith, and C.A. Kauffman Recognition and prevention of nosocomial invasive fungal infections in the intensive care unit Crit Care Med 38 8 Suppl. 2010 S380 S387
12. D.J.E. Marriott, E.G. Playford, S. Chen, M. Slavin, Q. Nquyen, and D. Ellis Determinants of mortality in non-neutropenic ICU patients with candidaemia Crit Care 13 2009 R115
13. M.D. Zilberberg, M.H. Kollef, H. Arnold, A. Labelle, S.T. Micek, and S. Kothari Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study BMC Infect Dis 10 2010 150
14. A.J. Labelle, S.T. Micek, N. Roubinian, and M.H. Kollef Treatment-related risk factors for hospital mortality in Candida bloodstream infections Crit Care Med 36 2008 2967 2972
15. W. Graninger, E. Presteril, B. Schneeweiss, B. Teleky, and A. Georgopoulos Treatment of Candida albicans fungaemia with fluconazole J Infect 26 1993 133 146 (Pubitemid 23129584)
16. R.E. Lewis Pharmacodynamic implications for use of antifungal agents Curr Opin Pharmacol 7 2007 491 497 (Pubitemid 47560215)
17. D. Andes In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis Antimicrob Agents Chemother 47 2003 1179 1186 (Pubitemid 36368572)
18. J. Roberts Importance of antibiotic dosing in critically ill patients Curr Pharm Biotechnol 2011 [Epub ahead of print]
19. M. Ulldemolins, J.A. Roberts, J. Lipman, and J. Rello Antibiotic dosing in multiple organ dysfunction syndrome Chest 139 2011 1210 1220
20. P.G. Pappas, C.A. Kauffman, D. Andes, D.K. Benjamin Jr., T.F. Calandra, and J.E. Edwards Jr. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America Clin Infect Dis 48 2009 503 535
21. D. Debruyne, and J.P. Ryckelynck Clinical pharmacokinetics of fluconazole Clin Pharmacokinet 24 1993 10 27 (Pubitemid 23042127)
22. D. Andes Clinical utility of antifungal pharmacokinetics and pharmacodynamics Curr Opin Infect Dis 17 2004 533 540 (Pubitemid 39627514)
23. D. Andes Clinical pharmacodynamics of antifungals Infect Dis Clin North Am 17 2003 635 649 (Pubitemid 38029157)
24. S.L.C.E. Buijk, I.C. Gyssens, J.W. Mouton, H.A. Verbrugh, D.J. Touw, and H.A. Bruining Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function Intensive Care Med 27 2001 115 121 (Pubitemid 32208977)
25. D.P. Nicolau, H. Crowe, C.H. Nightingale, and R. Quintiliani Bioavailability of fluconazole administered via a feeding tube in intensive care unit patients J Antimicrob Chemother 36 1995 395 401
26. A.S. Rosemurgy, S. Markowsky, S.E. Goode, K. Plastino, and R.E. Kearney Bioavailability of fluconazole in surgical intensive care unit patients: a study comparing routes of administration J Trauma 39 1995 445 447
27. W. Zhou, C.H. Nightingale, G.A. Davis, and D.P. Nicolau Absolute bioavailability of fluconazole suspension in intensive care unit patients J Infect Dis Pharmacother 5 2001 27 35 (Pubitemid 33098061)
28. J. Scholz, M. Schulz, M. Steinfath, S. Hover, and H. Bause Fluconazole is removed by continuous venovenous hemofiltration in a liver transplant patient J Mol Med (Berl) 73 1995 145 147
29. R. Bergner, M. Hoffmann, K.D. Riedel, G. Mikus, D.M. Henrich, and W.E. Haefeli Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg Nephrol Dial Transplant 21 2006 1019 1023
30. E. Muhl, T. Martens, H. Iven, P. Rob, and H.P. Bruch Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole Eur J Clin Pharmacol 56 2000 671 678 (Pubitemid 32204487)
31. M. Valtonen, E. Tiula, and P.J. Neuvonen Effect of continuous venovenous haemofiltration and haemodiafiltration on the elimination of fluconazole in patients with acute renal failure J Antimicrob Chemother 40 1997 695 700 (Pubitemid 27504001)
32. K. Yagasaki, S. Gando, N. Matsuda, T. Kameue, T. Ishitani, and T. Hirano Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration Intensive Care Med 29 2003 1844 1848 (Pubitemid 37373838)
33. S. Kishino, Y. Koshinami, T. Hosoi, N. Suda, Y. Takekuma, and S. Gandoh Effective fluconazole therapy for liver transplant recipients during continuous hemodiafiltration Ther Drug Monit 23 2001 4 8 (Pubitemid 32105958)
34. K. Wolter, G. Marggraf, H. Dermoumi, and E. Fritschka Elimination of fluconazole during continuous veno-venous haemodialysis (CVVHD) in a single patient Eur J Clin Pharmacol 47 1994 291 292 (Pubitemid 24330673)
35. P. Rajagopalan, R.K. Pelz, P.A. Lipsett, S.M. Swoboda, M.G. Rinaldi, and C.W. Hendrix Enteral fluconazole population pharmacokinetics in patients in the surgical intensive care unit Pharmacotherapy 23 2003 592 602 (Pubitemid 36539040)
36. D.P. Nicolau, H. Crowe, C.H. Nightingale, and R. Quintiliani Effect of continuous arteriovenous hemodiafiltration on the pharmacokinetics of fluconazole Pharmacotherapy 14 1994 502 505 (Pubitemid 24238185)
37. A.G. Prentice, and A. Glasmacher Making sense of itraconazole pharmacokinetics J Antimicrob Chemother 56 Suppl. 1 2005 i17 i22
38. J. Heykants, A. Van Peer, V. Van de Velde, P. Van Rooy, W. Meuldermans, and K. Lavrijsen The clinical pharmacokinetics of itraconazole: an overview Mycoses 32 Suppl. 1 1989 67 87
39. M. Hagihara, H. Kasai, T. Umemura, T. Kato, T. Hasegawa, and H. Mikamo Pharmacokinetic-pharmacodynamic study of itraconazole in patients with fungal infections in intensive care units J Infect Chemother 17 2011 224 230
40. B. Coronel, F. Persat, D. Dorez, J.F. Moskovtchenko, M.A. Peins, and A. Mercatello Itraconazole concentrations during continuous haemodiafiltration J Antimicrob Chemother 34 1994 448 449
41. L. Purkins, N. Wood, P. Ghahramani, K. Greenhalgh, M.J. Allen, and D. Kleinermans Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens Antimicrob Agents Chemother 46 2002 2546 2553 (Pubitemid 34793462)
42. P. Myrianthefs, S.L. Markantonis, P. Evaggelopoulou, S. Despotelis, E. Evodia, and D. Panidis Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study Int J Antimicrob Agents 35 2010 468 472
43. H. Quintard, E. Papy, L. Massias, S. Lasocki, P. Arnaud, and J.M. Desmonts The pharmacokinetic profile of voriconazole during continuous high-volume venovenous hemofiltration in a critically ill patient Ther Drug Monit 30 2008 117 119 (Pubitemid 351161110)
44. C. Robatel, M. Rusca, C. Padoin, O. Marchetti, L. Liaudet, and T. Buclin Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient J Antimicrob Chemother 54 2004 269 270 (Pubitemid 39029007)
45. V. Fuhrmann, P. Schenk, W. Jaeger, M. Miksits, N. Kneidinger, and J. Warszawska Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration J Antimicrob Chemother 60 2007 1085 1090 (Pubitemid 47617758)
46. I. Mohammedi, M.A. Piens, C. Padoin, and D. Robert Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients Eur J Clin Microbiol Infect Dis 24 2005 358 360 (Pubitemid 40897526)
47. W.W. Hope, E.M. Billaud, J. Lestner, and D.W. Denning Therapeutic drug monitoring for triazoles Curr Opin Infect Dis 21 2008 580 586
48. O. Burkhardt, S. Thon, J. Burhenne, T. Welte, and J.T. Kielstein Sulphobutylether-β-cyclodextrin accumulation in critically ill patients with acute kidney injury treated with intravenous voriconazole under extended daily dialysis Int J Antimicrob Agents 36 2010 93 94
49. M.A. von Mach, J. Burhenne, and L.S. Weilemann Accumulation of the solvent vehicle sulphobutylether β cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy BMC Clin Pharmacol 6 2006 6
50. F. Alvarez-Lerma, A. Allepuz-Palau, M.P. Gracia, M. Angeles Leon, A. Navarro, and H. Sanchez-Ruiz Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function J Chemother 20 2008 93 100 (Pubitemid 351428669)
51. V. Hafner, D. Czock, J. Burhenne, K.D. Riedel, J. Bommer, and G. Mikus Pharmacokinetics of sulfobutylether-β-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration Antimicrob Agents Chemother 54 2010 2596 2602
52. R. Bellmann Clinical pharmacokinetics of systemically administered antimycotics Curr Clin Pharmacol 2 2007 37 58 (Pubitemid 46723129)
53. H.A. Gallis, R.H. Drew, and W.W. Pickard Amphotericin B: 30 years of clinical experience Rev Infect Dis 12 1990 308 329 (Pubitemid 20118658)
54. R. Bellmann, P. Egger, W. Gritsch, R. Bellmann-Weiler, M. Joannidis, and N. Kaneider Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltration J Antimicrob Chemother 51 2003 671 681 (Pubitemid 36336162)
55. V. Heinemann, D. Bosse, U. Jehn, B. Kahny, K. Wachholz, and A. Debus Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients Antimicrob Agents Chemother 41 1997 1275 1280 (Pubitemid 27231426)
56. R. Bellmann, P. Egger, A. Djanani, and C.J. Wiedermann Pharmacokinetics of amphotericin B lipid complex in critically ill patients on continuous veno-venous haemofiltration Int J Antimicrob Agents 23 2004 80 83 (Pubitemid 38087961)
57. M. Tomlin, and G.S. Priestley Elimination of liposomal amphotericin by hemodiafiltration Intensive Care Med 21 1995 699 700
58. R. Bellmann, P. Egger, and C.J. Wiedermann Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalence Clin Infect Dis 36 2003 1500 1501 (Pubitemid 36702889)
59. D. Andes Antifungal agents pharmacokinetics and pharmacodynamics of amphotericin B C.H. Nightingale, T. Murakawa, P.G. Ambrose, G.L. Drusano, Antimicrobial pharmacodynamics in theory and clinical practice (Infectious disease and therapy) 2nd ed. 2007 Informa Healthcare New York, NY 315
60. J. Schonebeck, A. Polak, M. Fernex, and H.J. Scholer Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function Chemotherapy 18 1973 321 336
61. T.H. Ittel, U.F. Legler, A. Polak, W.M. Glockner, and H.G. Sieberth 5-Fluorocytosine kinetics in patients with acute renal failure undergoing continuous hemofiltration Chemotherapy 33 1987 77 84 (Pubitemid 17017086)
62. A.H. Lau, and N.O. Kronfol Elimination of flucytosine by continuous hemofiltration Am J Nephrol 15 1995 327 331
63. J.A. Roberts, A.A. Udy, S. O'Donoghue, S. Briscoe, D.L. Paterson, and J. Lipman Clearance of intravenous 5-fluorocytosine during continuous venovenous haemodiafiltration in a patient with hepatosplenic candidiasis Int J Antimicrob Agents 34 2009 383 384
64. A.H. Thomson, G. Shankland, C. Clareburt, and S. Binning Flucytosine dose requirements in a patient receiving continuous veno-venous haemofiltration Intensive Care Med 28 2002 999 (Pubitemid 34762245)
65. A. Vermes, H. van der Sijs, and H.J. Guchelaar Flucytosine: correlation between toxicity and pharmacokinetic parameters Chemotherapy 46 2000 86 94 (Pubitemid 30093541)
66. C. Wagner, W. Graninger, E. Presterl, and C. Joukhadar The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications Pharmacology 78 2006 161 177 (Pubitemid 44948055)
67. T. Gumbo Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies Curr Opin Infect Dis 20 2007 587 591 (Pubitemid 350059518)
68. O. Burkhardt, V. Kaever, H. Burhenne, and J.T. Kielstein Extended daily dialysis does not affect the pharmacokinetics of anidulafungin Int J Antimicrob Agents 34 2009 282 283
69. J.M. Leitner, B. Meyer, V. Fuhrmann, K. Saria, C. Zuba, and W. Jager Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration J Antimicrob Chemother 66 2011 880 884
70. K. Hirata, T. Aoyama, Y. Matsumoto, F. Ogawa, H. Yamazaki, and A. Kikuti Pharmacokinetics of antifungal agent micafungin in critically ill patients receiving continuous hemodialysis filtration Yakugaku Zasshi 127 2007 897 901 (Pubitemid 46684737)
71. S. Kishino, K. Ohno, T. Shimamura, and H. Furukawatodo Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients Clin Transplant 18 2004 676 680 (Pubitemid 39496980)
72. T.H. Nguyen, T. Hoppe-Tichy, H.K. Geiss, A.C. Rastall, S. Swoboda, and J. Schmidt Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit J Antimicrob Chemother 60 2007 100 106 (Pubitemid 47073282)
73. W.W. Hope, and G.L. Drusano Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside Clin Microbiol Infect 15 2009 602 612
74. T.I. Saari, K. Laine, M. Neuvonen, P.J. Neuvonen, and K.T. Olkkola Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl Eur J Clin Pharmacol 64 2008 25 30
75. J. Ahonen, K.T. Olkkola, A. Takala, and P.J. Neuvonen Interaction between fluconazole and midazolam in intensive care patients Acta Anaesthesiol Scand 43 1999 509 514 (Pubitemid 29232717)
76. P.J. Gandhi, P.A. Menezes, H.T. Vu, A.L. Rivera, and K. Ramaswamy Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient Am J Health System Pharm 60 2003 2479 2483 (Pubitemid 44712868)
77. D. Andes, A. Pascua, and O. Marchetti Antifungal therapeutic drug monitoring: established and emerging indications Antimicrob Agents Chemother 53 2009 24 34
78. J. Smith, and D. Andes Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations Ther Drug Monit 30 2008 167 172 (Pubitemid 351521643)
79. M.L. Goodwin, and R.H. Drew Antifungal serum concentration monitoring: an update J Antimicrob Chemother 61 2008 17 25
80. J.A. Roberts, M. Ulldemolins, M.S. Roberts, B. McWhinney, J. Ungerer, and D.L. Paterson Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept Int J Antimicrob Agents 36 2010 332 339